Scribble deficiency promotes pancreatic ductal adenocarcinoma development and metastasis Cold Spring Harbor Laboratory, NY, United States; Lustgarten Foundation, Pancreatic Cancer Research Laboratory, NY, United States.
Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, United Kingdom.
Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, United Kingdom.
Department of Gastroenterology, University Medical Centre Goettingen, Gastrointestinal Oncology and Endocrinology, Goettingen, Germany.
Department of Surgery, Universitätsklinikum Erlangen, Erlangen, Germany.
Institute for Pathology, University Hospital Carl Gustav Carus, Dresden, Germany; National Center for Tumor Diseases Dresden (NCT/UCC), Dresden, Germany.
Institute of Pathology, Universitätsklinikum Erlangen, Erlangen, Germany.
Institute of Pathology, Ludwig-Maximilians-Universität (LMU) Munich, Munich, Germany.
Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.
Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.
Department of Pathology, Royal Liverpool University Hospital, Liverpool, United Kingdom.
Department of Surgery, Friedrich-Alexander Universität Erlangen-Nürnberg (FAU), Erlangen, Germany.
Department of Biochemistry, Weill Cornell Medicine, NY, United States.
Department of Biochemistry and Chemistry, La Trobe Institute for Molecular Science, La Trobe University, VIC, Australia.
Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.
Cold Spring Harbor Laboratory, NY, United States; Lustgarten Foundation, Pancreatic Cancer Research Laboratory, NY, United States.
Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, United Kingdom.
Visa övriga samt affilieringar
2024 (Engelska) Ingår i: Cancer Research, ISSN 0008-5472, E-ISSN 1538-7445, Vol. 84, nr 18, s. 2968-2984Artikel i tidskrift (Refereegranskat) Published
Abstract [en]
Perturbation of cell polarity is a hallmark of pancreatic ductal adenocarcinoma (PDAC) progression. Scribble (SCRIB) is a well-characterized polarity regulator that has diverse roles in the pathogenesis of human neoplasms. To investigate the impact of SCRIB deficiency in PDAC development and progression, Scrib expression was genetically ablated in well-established mouse models of PDAC. Scrib loss in combination with KrasG12D did not influence development of pancreatic intraepithelial neoplasms in mice. However, Scrib deletion cooperated with KrasG12D and concomitant Trp53 heterozygous deletion to promote invasive PDAC and metastatic dissemination, leading to reduced overall survival. Immunohistochemical and transcriptome analyses revealed that Scrib-null tumors display a pronounced reduction of collagen content and an abundance of cancer-associated fibroblasts (CAF). Mechanistically, IL1α levels were reduced in Scrib-deficient tumors, and Scrib knockdown downregulated IL1α in mouse PDAC organoids (mPDO), which impaired CAF activation. Furthermore, Scrib loss increased YAP activation in mPDOs and established PDAC cell lines, enhancing cell survival. Clinically, SCRIB expression was decreased in human PDAC, and SCRIB mislocalization was associated with poorer patient outcome. These results indicate that SCRIB deficiency enhances cancer cell survival and remodels the tumor microenvironment to accelerate PDAC development and progression, establishing the tumor suppressor function of SCRIB in advanced pancreatic cancer.
Significance: SCRIB loss promotes invasive pancreatic cancer development via both cell-autonomous and non-cell-autonomous processes and is associated with poorer outcomes, denoting SCRIB as a tumor suppressor and potential biomarker for the prediction of recurrence.
Ort, förlag, år, upplaga, sidor American Association For Cancer Research (AACR), 2024. Vol. 84, nr 18, s. 2968-2984
Nationell ämneskategori
Cancer och onkologi
Identifikatorer URN: urn:nbn:se:umu:diva-230017 DOI: 10.1158/0008-5472.CAN-23-3419 ISI: 001313818100005 Scopus ID: 2-s2.0-85204258425 OAI: oai:DiVA.org:umu-230017 DiVA, id: diva2:1903519
Forskningsfinansiär NIH (National Institutes of Health), 5P30CA45508 NIH (National Institutes of Health), R01CA249002 NIH (National Institutes of Health), U01CA224013 NIH (National Institutes of Health), U01CA210240 NIH (National Institutes of Health), 1R01CA188134 2024-10-042024-10-042024-10-08 Bibliografiskt granskad